Lippincott, Christopher K.
Perry, Allison
Munk, Elizabeth
Maltas, Gina
Shah, Maunank
Funding for this research was provided by:
National Institutes of Health (R44MD010521)
Article History
Received: 20 June 2022
Revised: 23 September 2022
Accepted: 7 October 2022
First Online: 26 October 2022
Declarations
:
: The study protocol was approved by the Johns Hopkins Medicine Institutional Review Board (IRB00174219). Informed consent was waived by the Johns Hopkins Medicine Institutional Review Board due to the retrospective observational nature of this study. All methods and procedures were approved by the IRB and carried out in accordance with the IRB’s guidelines and regulations.
: Not applicable.
: MS are among the inventors of the vDOT technology licensed to emocha Mobile Health Inc. Under a license agreement between emocha Mobile Health Inc. and the Johns Hopkins University (JHU; Baltimore, MD, USA), MS and JHU are entitled to royalties related to technology described in this study. Specific to this study, MS did not and will not receive royalties or compensation from emocha Mobile Health Inc (Baltimore, MD, USA). Also, JHU owns equity in eMocha. This arrangement has been reviewed and approved by JHU in accordance with its conflict of interest policies. As per JHU IRB and Conflicts of Interest office (COI), conflicted study team members (MS) were excluded from accessing the original data set. Oversight of data management, including primary analyses and audit of all data analyses, were done by non-conflicted designees (GM, EM, CL), as approved by the JHU IRB and COI office. AP, GM, EM and CL do not have any conflict of interest.